PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9372119

Secondary malignancies.

G Socié
View original source ↗Export metadata ↓

Abstract

Malignant diseases are of particular concern as increasing numbers of patients survive the early phase after transplantation and remain free of their original disease. This article summarizes recent articles published on this topic, with particular emphasis on those published during the past 12-month review period. These recent clinical and biologic data on secondary malignancies (leukemia, lymphoma, and solid tumors) occurring after either allogeneic or autologous stem cell transplantation are summarized in this review.

Explore related subjects

Hematologic NeoplasmsHematopoietic Stem Cell TransplantationHumansNeoplasms, Second PrimaryTransplantation, AutologousTransplantation, HomologousJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G Socié. 1996. Secondary malignancies.. https://doi.org/10.1097/00062752-199603060-00011

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.

Allogeneic hematopoietic cell transplantation (HCT) following nonmyeloablative conditioning has been extensively evaluated in patients with hematologic malignancies who are ineligible for conventional HCT because of age or medical comorbidities. Nonmyeloablative regimens have led to an initial state of mixed hematopoietic chimerism defined as coexistence of donor- and host-derived hematopoiesis. While nonmyeloablative regimens have been associated with reduced regimen-related toxicities in comparison with conventional myeloablative conditioning, graft rejection, graft-versus-host disease (GVHD), and disease progression have remained significant challenges. In this article, after briefly introducing current techniques for chimerism assessment, we describe factors affecting donor chimerism levels after nonmyeloablative conditioning, and then review data suggesting that chimerism assessment early after HCT might help identify patients at risk for graft rejection, GVHD and relapse/progression. Finally, we discuss how these observations have opened the way to further research protocols evaluating manipulation of postgrafting immunosuppression, and/or infusion of donor immune cells.

Hematologic Neoplasms↗
PubMed2006

Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

The cAMP signalling pathway has emerged as a key regulator of haematopoietic cell proliferation, differentiation and apoptosis. In parallel, general understanding of the biology of cyclic nucleotide PDEs (phosphodiesterases) has advanced considerably, revealing the remarkable complexity of this enzyme system that regulates the amplitude, kinetics and location of intracellular cAMP-mediated signalling. The development of therapeutic inhibitors of specific PDE gene families has resulted in a growing appreciation of the potential therapeutic application of PDE inhibitors to the treatment of immune-mediated illnesses and haematopoietic malignancies. This review summarizes the expression and function of PDEs in normal haematopoietic cells and the evidence that family-specific inhibitors will be therapeutically useful in myeloid and lymphoid malignancies.

Hematologic Neoplasms↗
PubMed2006

Changed times at Hematological Oncology.

This editorial describes the changes to Hematological Oncology over the past 12 months and redefines the scope and the goals of the journal. As well as changes in format, an electronic manuscript submission system and a stringent peer-review policy (outlined here) have been implemented. The journal is a vehicle for high-quality articles in the broad field of experimental and clinical hematological oncology, and a medium for the publication of translational research. As well as submitted material, the journal solicits and publishes high-quality reviews from leading experts.

Hematologic Neoplasms↗